NanoPeptide (Qingdao) Biotechnology Ltd. was initiated and founded by Professor Chen Pu, a member of the Canadian Academy of Engineering, in June 2017. Our company aims to develop new biopharmaceuticals by nanotechnology, devotes itself to research and development of siRNA, an internationally leading precision medical product, provides targeted gene-based drugs and immunotherapeutic drugs for cancer treatment. At the same time, our company develops efficient low-toxic nanopeptide drug delivery systems for targeted treatment of multiple diseases. Our company has published over 200 SCI academic papers.